Мы используем Cookies Этот веб-сайт использует cookie-файлы, чтобы предлагать вам наиболее актуальную информацию. Просматривая этот веб-сайт, Вы принимаете cookie-файлы.
This favorable survival result was seen in most prespecified subgroups for pralatrexate.
2
These results indicate that pralatrexate is generally well tolerated and effective in Japanese patients with relapsed or refractory peripheral T-cell lymphoma.
3
A trend toward improvement in OS favoring pralatrexate was observed with an HR of 0.84 (95% confidence interval: 0.61-1.14) in the intent-to-treat population.
4
Pralatrexate is a novel antifolate approved in the USA for the treatment of relapsed or refractory peripheral T-cell lymphoma.
5
Pralatrexate, which has already received FDA's orphan drug status to treat T-cell lymphoma, is being tested as a treatment for large B-cell lymphoma.